D-0328-2022 Class II Terminated

Recalled by Perrigo Company PLC — Allegan, MI

FDA drug recall D-0328-2022 was initiated by Perrigo Company PLC on Jul 27, 2021 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications; Out of specification result obtained for impurity A during stability testing. The recall status is terminated (terminated Nov 8, 2022). Affected quantity: 55,032 units.

Recall details

Product Type
Drugs
Report Date
Jan 12, 2022
Initiation Date
Jul 27, 2021
Termination Date
Nov 8, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
55,032 units

Product description

EQUALINE aller-ease fexofenadine hydrochloride tablets, 180 mg, 24 HR, packaged as a) 15 count bottle, NDC 41163-571-22, UPC 0 41163 48067 4; b) 70 tablets per bottle, NDC 41163-571-01, UPC 0 41163 49847 1; Made in the Czech Republic, Distributed by: UNFI Providence, RI 02908.

Reason for recall

Failed Impurities/Degradation Specifications; Out of specification result obtained for impurity A during stability testing.

Distribution pattern

Nationwide in the USA

Code information

Lot # a)0HE2530 Exp 12/31/2021, 0KE2980 EXP 02/28/2022 b)0FR0461 Exp 2/28/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0328-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0328-2022. Report a data issue: hello@regdatalab.com.